Immunobiology of tumor necrosis factor receptor superfamily (original) (raw)

References

1. Chan KF, Siegel MR, Lenardo JM: Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000;13:419–422.
   Article PubMed CAS Google Scholar
2. Nagata S: Apoptosis by death factor. Cell 1997;88:355–365.
   Article PubMed CAS Google Scholar
3. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fasantigen that mediates apoptosis. Nature 1992;356:314–317.
   Article PubMed CAS Google Scholar
4. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76; 969–976.
   Article PubMed CAS Google Scholar
5. Zhou T, Edwards CK 3rd, Yang P, Wang Z, Bluethmann H, Mountz JD: Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996;156:2661–2665.
   PubMed CAS Google Scholar
6. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y: Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001;166:1314–1319.
   PubMed CAS Google Scholar
7. Song K, Chen Y, Goke R, Wilmen A, Seidel C, Goke A, Hilliard B: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000;191: 1095–1104.
   Article PubMed CAS Google Scholar
8. Chimaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, Xing L, Gentz R, Ni J, Dixit VM: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;274:990–992.
   Article Google Scholar
9. Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, Vincenz C, Aggarwal BB, Ni J, Dixit VM: Identification and functional characterization ov DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998;431:351–356.
   Article PubMed CAS Google Scholar
10. Wang EC, Thern A, Denzel A, Kitson J, Farrow SN, Owen MJ: DR3 regulates negative selection during thymocyte development. Mol Cell Biol 2001;21: 3451–3461.
    Article PubMed CAS Google Scholar
11. Liu J, Na S, Glasebrook A, Fox N, Solenberg PJ, Zhang Q, Song HY, Yang DD: Enhanced CD4+T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity 2001;15:23–34.
    Article PubMed CAS Google Scholar
12. Amakawa R, Hakem A, Kundig TM, et al: Impaiored negativeselection of T cells in Hodgkin's diseaseantigen CD30-deficient mice. Cell 1996;84:551–562.
    Article PubMed CAS Google Scholar
13. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J: CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000;1:433–440.
    Article PubMed CAS Google Scholar
14. Yang FC, Agematsu K, Nakazawa T, Mori T, Ito S, Kobata T, Morimoto C, Komiyama A: CD27/CD70 interaction directly induces natural killer cell killing activity. Immunology 1996;88:289–293.
    Article PubMed CAS Google Scholar
15. Durie FH, Foy TM, Noelle RJ: The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease. Res Immunol 1994;145: 200–205; disc ussion 244–249.
    Article PubMed CAS Google Scholar
16. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16: 111–135.
    Article PubMed CAS Google Scholar
17. Harrop JA, McDonnell PC, Brigham-Burke M, et al: Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998; 273:27,548–27,556.
    Article CAS Google Scholar
18. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF: LIGHT, a new member of the TNF superfamily, and lymphotoxinalpha are ligands for herpesvirusentry mediator. Immunity 1998;8:21–30.
    Article PubMed CAS Google Scholar
19. Tamada K, Shimozaki K, Chapoival AI, Zhai Y, Su J, Chen SF, Hsieh SL, Nagata S, Ni J, Chen L: LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cellmediatedallogeneic T cell proliferation and is required for dendritic cell-mediatedallogeneic T cell response. J Immunol 2000;164:4105–4110.
    PubMed CAS Google Scholar
20. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M, Cheroutre H, Ware CF: Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001;167: 6330–6337.
    PubMed CAS Google Scholar
21. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111–2114
    Article PubMed CAS Google Scholar
22. Thompson JS, Bixler SA, Qian F, et al: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108–2111.
    Article PubMed CAS Google Scholar
23. Khare SD, Sarosi I, Xia XZ, et al: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97:3370–3375.
    Article PubMed CAS Google Scholar
24. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999:190: 1697–1710.
    Article PubMed CAS Google Scholar
25. Rooney IA, Butrovich KD, Glass AA, Borboroglu S, Benedict CA, Whitbeck JC, Cohen GH, Eisenberg RJ, Ware CF: The lymphotoxin-beta receptorrisnecessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000;275:14,307–14,315.
    Article CAS Google Scholar
26. Ettinger R, Browning JL, Michie SA, van Ewijk W, McDevitt HO: Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein. Proc Natl Acad Sci USA 1996;93:13,102–13,107.
    Article CAS Google Scholar
27. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel membero of the tumor necrosis factor family. Cell 1993;75: 1169–1178.
    Article PubMed CAS Google Scholar
28. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encodedby the cDNA forhuman cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233–243.
    Article PubMed CAS Google Scholar
29. Zhou T, Bluethmann H, Eldridge J, Brockhaus M, Berry K, Mountz JD: Abnormal thymocyte development and production of autoreactive T cells in T cell receptor transgenic autoimmune mice. J Immunol 1991;147:466–474.
    PubMed CAS Google Scholar
30. Zhou T, Bluethmann H, Zhang J, Edwards CK 3rd, Mountz JD: Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice. J Exp Med 1992;176:1063–1072.
    Article PubMed CAS Google Scholar
31. Zhou T, Edwards CK 3rd, Mountz JD: Prevention of age-related T cell apoptosis defect in CD2-fastransgenic mice. J Exp Med 1995; 182:129–137.
    Article PubMed CAS Google Scholar
32. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806–809.
    Article PubMed CAS Google Scholar
33. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S: Lathal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158: 2303–2309
    PubMed CAS Google Scholar
34. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997;100:1951–1957.
    Article PubMed CAS Google Scholar
35. Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S, Tani Y, Watanabe M, Shiraishi A, Nishioka K, Yonehara S, Serizawa N: A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000; 12:555–562.
    Article PubMed CAS Google Scholar
36. Fujisawa K, Asahara H, Okamoto K, Aono H, Hasumuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T, Nishioka K: Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J Clin Invest 1996;98:271–278.
    PubMed CAS Google Scholar
37. Zhou T, Song L, Yang P, Wang Z, Lui D, Jope RS: Bisindolylmaleimide VIII facilitates Fasmediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat Med 1999;5:42–48.
    Article PubMed CAS Google Scholar
38. Zhang HG, Liu D, Heike Y, Yang P, Wang Z, Wang X, Curiel DT, Zhou T, Mountz JD: Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol 1998;16: 1045–1049.
    Article PubMed CAS Google Scholar
39. Zhang HG, Su X, Liu D, Liu W, Yang P, Wang Z, Edwards CK, Bluethmann H, Mountz JD, Zhou T: Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999;162:1423–1430.
    PubMed CAS Google Scholar
40. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.
    Article PubMed CAS Google Scholar
41. Gura T: How TRAIL kills cancer cells, but not normal cells. Science 1997;277:768.
    Article PubMed CAS Google Scholar
42. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L: Death receptor 5, a new memberof the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaß pathway. Immunity 1997;7:821–830.
    Article PubMed CAS Google Scholar
43. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386–5397.
    Article PubMed CAS Google Scholar
44. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependentapoptosis and activate NF-kappaB. Immunity 1997;7:831–836.
    Article PubMed CAS Google Scholar
45. Degli-Esposti MA, Smolak PJ, Walezak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA: Cloning and characterization of TRAIL-R3, a novel memberof the emerging TRAIL receptor family. J Exp Med 1997;186: 1165–1170.
    Article PubMed CAS Google Scholar
46. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG: The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813–820.
    Article PubMed CAS Google Scholar
47. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273: 14,363–14,367.
    Article CAS Google Scholar
48. Kuang AA, Diehl GE, Zhang J, Winoto A: FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000;275:25,065–25,068.
    Article CAS Google Scholar
49. Muhlenbeck F, Haas E, Schwenzer R, Schubert G, Grell M, Smith C, Scheurich P, Wajant H: TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 1998;273:33,091–33,098.
    Article CAS Google Scholar
50. Jeremias I, Debatin KM: TRAIL induce sapoptosis and activation of NF kappa B. Eur Cytokine Netw 1998;9:687–688.
    PubMed CAS Google Scholar
51. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157–163.
    Article PubMed CAS Google Scholar
52. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–162.
    PubMed CAS Google Scholar
53. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661–670.
    Article PubMed CAS Google Scholar
54. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K: Critical role for tumornecrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195: 161–169.
    Article PubMed CAS Google Scholar
55. Miura Y, Misawa N, Maeda N, Inagaki Y, Tanaka Y, Ito M, Kayagaki N, Yamamoto N, Yagita H, Mizusawa H, Koyanagi Y. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med 2001;193: 651–660.
    Article PubMed CAS Google Scholar
56. Martinez-Lorenzo MJ, Alaza MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J, Anel A: Involvement of APO2 ligand/TRAIL inactivation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998; 28:2714–2725.
    Article PubMed CAS Google Scholar
57. Ichikawa K, Liu W, zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T: Tumoricidal activity of a novelanti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954–960.
    Article PubMed CAS Google Scholar
58. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564–567.
    Article PubMed CAS Google Scholar
59. Moore PA, Belvedere O, Orr A, et al: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260–263.
    Article PubMed CAS Google Scholar
60. Shu HB, Hu WH, Johnson H: TALL-1 is a novel member of the TNF family thatisdown-regulated by mitogens. J Leukoc Biol 1999;65:680–683.
    PubMed CAS Google Scholar
61. Schneider P, MacKay F, Steiner V, et al.: BAFF, a novel ligand of the tumornecrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747–1756.
    Article PubMed CAS Google Scholar
62. Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB: Identification and characterization of a novel cytokine, TH ANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999;274:15,978–15,981.
    Article CAS Google Scholar
63. Gross JA, Johnston J, Mudri S, et al: TACI and BCMA are receptors for a TNF homologue implicated in B-cell auto immune disease. Nature 2000;404:995–999.
    Article PubMed CAS Google Scholar
64. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198–204.
    Article PubMed CAS Google Scholar
65. Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM: Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000;1:37–41.
    Article PubMed CAS Google Scholar
66. Yu G, Boone T, Delaney J, et al: APRIL and TALL-1 and receptors BCMA and TAC1: system for regulating humoral immunity. Nat Immunol 2000;1:252–256.
    Article PubMed CAS Google Scholar
67. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, Cancro M, Grewal IS, Dixit VM. Identification of a novel receptor for B lymphocyte stimulator that ismulated inamouse strain with severe B cell deficiency. Curr Biol 2001;11:1547–1552.
    Article PubMed CAS Google Scholar
68. Wu Y, Bressette D, Carrell JA, et al: Tumor necrosis factor (TNF) receptor superfamily member TAC1 is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000;275: 35,478–37,485.
    CAS Google Scholar
69. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000;10:785–788.
    Article PubMed CAS Google Scholar
70. von Bulow GU, van Deursen JM, Bram RJ: Regulation of the T-independent humoral response by TACI. Immunity 2001;14:573–582.
    Article Google Scholar
71. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM: Activation and accumulation of B cells in TACI-deficientmice. Nat Immunol 2001;2:638–643.
    Article PubMed CAS Google Scholar
72. Xu S, Lam KP: B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001;21:4067–4074.
    Article PubMed CAS Google Scholar
73. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T: Cutting edge: a role for B lymphocyte stimulator in systemic lupus ery thematosus. J Immunol 2001;166:6–10.
    PubMed CAS Google Scholar
74. Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44: 1313–1319.
    Article PubMed CAS Google Scholar
75. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001;2:632–637.
    Article PubMed CAS Google Scholar

Download references